ceftolozane (Zerbaxa) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ceftolozane is a novel a cephalosporin-class antibacterial drug. In combination with a beta-lactamase inhibitor tazobactam (ZERBAXA, ceftolozane/tazobactam ) ceftolozane, is currently indicated for the treatment of the adult patients with complicated intra-abdominal infections caused by designated Gram-negative and Gram-positive microorganisms and complicated urinary tract infections caused by certain Gram-negative bacteria, including those caused by multi-drug resistant Pseudomonas aeruginosa. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. Safety and effectiveness in pediatric patients have not been established.   NCATS

Chemistry

  • SMILES: Cn1c(N)c(NC(=O)NCCN)c[n+]1CC2=C(N3[C@H](SC2)[C@H](NC(=O)\C(=N/OC(C)(C)C(=O)[O-])\c4nsc(N)n4)C3=O)C(=O)O
  • InChIKey: JHFNIHVVXRKLEF-DCZLAGFPSA-N
  • Mol. Mass: 666.7
  • ALogP: -3.9
  • ChEMBL Molecules:
    ceftolozane  
    ceftolozane sulfate  
More Chemistry

Pharmacology

Combination drugs

( ceftolozane (Zerbaxa), tazobactam (Zosyn) - other name: ceftolozane and tazobactam )

Alternative names

(6r,7r)-3-([3-amino-4-(2-aminoethylcarbamoylamino)-2-methylpyrazol-1-ium-1-yl]methyl)-7-([(2z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | ceftolozane | ceftolozane sulfate | ceftolozane sulfate / tazobactam sodium | cxa-101 | cxa-201 | fr264205 | fr 264205 | fr-264205 | fr26 4205 | pdc339

Organizations (19)

Research & Development (18)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (26)

Approved Indications (2)


 

Intraabdominal Infections (approved 2014)

Pyelonephritis (approved 2014)

Experimental Indications - Clinical Trial Phases 1-4 (26)


 

Bacteremia (Phase 3)

Bacterial Infections (Phase 3)

Bronchiectasis (Phase 4)

Burkholderia Infections (Phase 4)

Burns (Phase 4)

Critical Illness (Phase 1)

Cystic Fibrosis (Phase 4)

Diabetes Mellitus (Phase 1)

Febrile Neutropenia (Phase 4)

Gastritis (Phase 2)

General Surgery (Phase 1)

Healthcare-Associated Pneumonia (Phase 3)

Healthy Volunteers (Phase 1)

Hematologic Neoplasms (Phase 1/Phase 2)

Infections (Phase 2)

Intraabdominal Infections (Phase 3)

Lung Diseases (Phase 3)

Neoplasms (Phase 4)

Pharmacokinetics (Phase 4)

Pneumonia (Phase 1/Phase 2)

Pneumonia, Ventilator-Associated (Phase 3)

Pseudomonas aeruginosa (Phase 4)

Pseudomonas Infections (Phase 4)

Pyelonephritis (Phase 3)

Urinary Tract Infections (Phase 3)

Wound Infection (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial Organizations: 18

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue